Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries
Authors:
- G. GeorgeGGG. George
- D. EntingDED. Enting
- H. GarmoHGH. Garmo
- P. StattinPSP. Stattin
- I.F. LissbrantILI.F. Lissbrant
- M. Monroy-IglesiasMMM. Monroy-Iglesias
- L.-M. ScailteuxLSL.-M. Scailteux
- F. BalussonFBF. Balusson
- C. Van PraetCPC. Van Praet
- N. LumenNLN. Lumen
- G. MarvasoGMG. Marvaso
- G. CorraoGCG. Corrao
Open Access
- 4 March 2025
- journal article
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 7
Abstract
No abstract availableKeywords
Funding Information
- Vetenskapsrådet (2017-00847)
- Ipsen Pharma SAS
- Cancerfonden (2019-0030)
This publication has 11 references indexed in Scilit:
- Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practiceTherapies, 2023
- LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trialProstate Cancer and Prostatic Diseases, 2022
- Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancerScandinavian Journal of Urology, 2021
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerNew England Journal of Medicine, 2018
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyEuropean Urology, 2017
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2015
- Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?World Journal of Urology, 2014
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor GrowthCancer Research, 2008
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerBritish Journal of Cancer, 2004